In an effort to describe the real-world clinical impact of positive findings in ATM, CHEK2, PALB2, and other DDR genes in a cohort of breast and/or ovarian cancer patients, we describe whether provider-reported clinical recommendations changed, and which interventions were recommended based on genetic testing results. The gene discussed is ATM; the disease is ovarian cancer.